Assessment of response to oral metaproterenol sulfate by forced oscillation in young children.

Author: BairnsfatherL, HilmanB C, MenonP, MenonV

Paper Details 
Original Abstract of the Article :
The dose response characteristics and side effects of three doses of oral metaproterenol sulfate (MS) (0.4, 0.6, and 0.8 mg/kg) were compared with a placebo in ten asthmatic children (3 to 6 years). The bronchodilator efficacy was objectively assessed by evaluating the decrease in mean total respira...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/3382060

データ提供:米国国立医学図書館(NLM)

Evaluating Oral Metaproterenol Sulfate in Young Children

This study examines the dose response characteristics and side effects of oral metaproterenol sulfate (MS), a bronchodilator medication used to treat asthma, in young children aged 3 to 6 years. The researchers compared the bronchodilator efficacy of three doses of MS (0.4, 0.6, and 0.8 mg/kg) with placebo using forced oscillation technique, a non-invasive method for measuring airway resistance in young children. The study aimed to assess the effectiveness and safety of MS in this age group, where dosage recommendations are often limited.

Oral Metaproterenol Sulfate Effective in Young Children

The study found that oral MS was effective in improving airway function in young children with asthma. All three doses of MS were more effective than placebo in decreasing mean total respiratory resistance (MTRR), a measure of airway obstruction. This suggests that oral MS can be a valuable treatment option for young children with asthma.

The Need for Precise Dosage Recommendations

The study highlights the need for precise dosage recommendations for bronchodilators, such as oral MS, in young children. The lack of clear guidelines for this age group is attributed to challenges in objectively measuring bronchodilator response and concerns about potential side effects. This research emphasizes the importance of developing effective and safe treatment strategies for young children with asthma.

Dr.Camel's Conclusion

Just as a camel carefully navigates a challenging desert landscape, healthcare providers must navigate the delicate terrain of treating young children with asthma. This study provides valuable insights into the effectiveness of oral MS in this age group, highlighting the need for more research to develop precise dosage recommendations and ensure safe and effective treatment for young patients with asthma.

Date :
  1. Date Completed 1988-07-18
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

3382060

DOI: Digital Object Identifier

3382060

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.